About galapagos nv - GLPG
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
GLPG At a Glance
Galapagos NV
Industriepark Mechelen Noord
Mechelen, Brussels Region 2800
| Phone | 32-1-534-29-00 | Revenue | 1.26B | |
| Industry | Biotechnology | Net Income | 362.14M | |
| Sector | Health Technology | 2025 Sales Growth | 320.992% | |
| Fiscal Year-end | 12 / 2026 | Employees | 452 | |
| View SEC Filings |
GLPG Valuation
| P/E Current | 5.328 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 5.95 |
| Price to Sales Ratio | 1.717 |
| Price to Book Ratio | 0.567 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.307 |
| Enterprise Value to Sales | -1.082 |
| Total Debt to Enterprise Value | -0.006 |
GLPG Efficiency
| Revenue/Employee | 2,777,120.727 |
| Income Per Employee | 801,200.458 |
| Receivables Turnover | 20.089 |
| Total Asset Turnover | 0.303 |
GLPG Liquidity
| Current Ratio | 20.109 |
| Quick Ratio | 19.961 |
| Cash Ratio | 19.613 |
GLPG Profitability
| Gross Margin | 92.664 |
| Operating Margin | 42.226 |
| Pretax Margin | 27.051 |
| Net Margin | 28.85 |
| Return on Assets | 8.706 |
| Return on Equity | 10.605 |
| Return on Total Capital | 9.468 |
| Return on Invested Capital | 10.582 |
GLPG Capital Structure
| Total Debt to Total Equity | 0.214 |
| Total Debt to Total Capital | 0.213 |
| Total Debt to Total Assets | 0.203 |
| Long-Term Debt to Equity | 0.16 |
| Long-Term Debt to Total Capital | 0.16 |